ZenTech has signed strategic agreement to transfer its portfolio of radioimmunoassays (RIA) to DIAsource ImmunoAssays, a BioVendor group company.

immunotube

Image: ZenTech has agreed to transfer its portfolio of radioimmunoassay to DIAsource ImmunoAssays. Photo: courtesy of greschoj / FreeImages.

ZenTech, a Belgian biotech company specialized in the development, production and commercialization of solutions for clinical diagnostics of early life stage diseases and newborn screening, and DIAsource ImmunoAssays, a leading diagnostics company delivering manual RIA and ELISA kits and open automation solutions to international markets, today announced a strategic agreement, under which ZenTech will transfer its portfolio of RIA products to DIAsource, securing the continued production and sales of these products.

ZenTech has strategically reoriented itself to focus on newborn screening and early life stage diseases. DIAsource is the second largest supplier of radioimmunoassays in the world, committed to servicing customers worldwide that use manual ELISA and RIA assays and open automation to complement their portfolio on closed automated systems.

Both Belgian companies have long standing collaborations for more than 15 years, whereby DIAsource already managed part of the commercialization of the Zentech portfolio successfully. The current transfer of the RIA products from Zentech to DIAsource is a logical next step in line with the strategies of both companies. The portfolio to be transferred includes the complete line of specialty radioimmunoassays with thyroid markers and markers for fertility and salt balance.

In order to support a smooth transition with minimal disruption for customers, the companies have agreed to a transition period. Effective today 24th of July 2018 DIAsource ImmunoAssays assumes commercial ownership of the RIA product portfolio and will service clients from order to shipment, whereby ZenTech remains the manufacturer during the transition period in which the production will be transferred to DIAsource. The latter will be done in close collaboration and in phases and concluded by 30 September 2019.

Jean-Claude Havaux, Chaiman of the Board, ZenTech, said: “Historically, ZenTech had a background and expertise in radioimmunoassays. However, when ZenTech acquired the Belgian company Gamma in 2011, it got access to new technologies and entered the market of newborn screening and early life stage diseases.”

Jef Vangenechten, CEO of DIAsource ImmunoAssays, said: “This acquisition is yet another step in our strategy to position DIAsource as a consolidator of manual specialty assays, after previous acquisitions of the Intertech RIA product line in 2012 and Viro-Immun ELISA and IFA product lines in 2017.”

DIAsource also acquired the RIA client businesses from distribution partners in France and Spain in 2015 and 2016. This fourth acquisition in the RIA space demonstrates our commitment to the long term future servicing and support of our large RIA customer base worldwide.”

ZenTech has a broad portfolio of products in prenatal, neonatal and pediatric screening and offers complete and flexible solutions to set up the screening activity. The company exports more than 95% of its production, especially to Middle East and South East Asia, China, South America and Africa.

Source: Company Press Release